Charles Lucien Bonaparte, younger brother
of Napoleon Bonaparte, was the first to establish the proteinaceous nature of
snake venom in 1843.
Proteins constitute
90-95% of venom's dry weight and they are responsible for almost all of its
biological effects. Among hundreds, even thousands of proteins found in venom,
there are toxins, neurotoxins in particular, as well as nontoxic proteins
(which also have pharmacological properties), and many enzymes, especially
hydrolytic ones.[2] Enzymes (molecular weight 13-150 KDa) make-up 80-90% of
viperid and 25-70% of elapid venoms: digestive hydrolases, L-amino acid
oxidase, phospholipases, thrombin-like pro-coagulant, and kallikrein-like
serine proteases and metalloproteinases (hemorrhagins), which damage vascular
endothelium. Polypeptide toxins (molecular weight 5-10 KDa) include cytotoxins,
cardiotoxins, and postsynaptic neurotoxins (such as α-bungarotoxin and
α-Cobratoxin), which bind to acetylcholine receptors at neuromuscular
junctions. Compounds with low molecular weight (up to 1.5 KDa) include metals,
peptides, lipids, nucleosides, carbohydrates, amines, and oligopeptides, which
inhibit angiotensin converting enzyme (ACE) and potentiate bradykinin (BPP).
Inter- and intra-species variation in venom chemical composition is geographical
and ontogenic.[3] Phosphodiesterases interfere with the prey's cardiac system,
mainly to lower the blood pressure. Phospholipase A2 causes hemolysis by lysing
the phospholipid cell membranes of red blood cells.[6] Amino acid oxidases and
proteases are used for digestion. Amino acid oxidase also triggers some other
enzymes and is responsible for the yellow colour of the venom of some species.
Hyaluronidase increases tissue permeability to accelerate absorption of other
enzymes into tissues. Some snake venoms carry fasciculins, like the mambas
(Dendroaspis), which inhibit cholinesterase to make the prey lose muscle
control.[7]
MAIN ENZYMES OF SNAKE
VENOM
TYPE
|
NAME
|
ORIGIN
|
Oxydoreductases
|
dehydrogenase lactate
|
Elapidae
|
L-amino-acid oxidase
|
All species
|
|
Catalase
|
All species
|
|
Transferases
|
Alanine amino
transferase
|
|
Hydrolases
|
Phospholipase A2
|
All species
|
Lysophospholipase
|
Elapidae, Viperidae
|
|
Acetylcholinesterase
|
Elapidae
|
|
Alkaline phosphatase
|
Bothrops atrox
|
|
Acid phosphatase
|
Deinagkistrodon
acutus
|
|
5'-Nucleotidase
|
All species
|
|
Phosphodiesterase
|
All species
|
|
Deoxyribonuclease
|
All species
|
|
Ribonuclease 1
|
All species
|
|
Adenosine
triphosphatase
|
All species
|
|
Amylase
|
All species
|
|
Hyaluronidase
|
All species
|
|
NAD-Nucleotidase
|
All species
|
|
Kininogenase
|
Viperidae
|
|
Factor-X activator
|
Viperidae, Crotalinae
|
|
Heparinase
|
Crotalinae
|
|
α-Fibrinogenase
|
Viperidae, Crotalinae
|
|
β-Fibrinogenase
|
Viperidae, Crotalinae
|
|
α-β-Fibrinogenase
|
Bitis gabonica
|
|
Fibrinolytic enzyme
|
Crotalinae
|
|
Prothrombin activator
|
Crotalinae
|
|
Collagenase
|
Viperidae
|
|
Elastase
|
Viperidae
|
|
Lyases
|
Glucosamine ammonium
lyase
|
TOXINS
NUEROTOXINS
A) An exchange of ions (charged atoms) across
the nerve cell membrane sends a depolarising current towards the end of the
nerve cell (cell terminus).
B) When the
depolarising current arrives at the nerve cell terminus, the neurotransmitter
acetylcholine (ACh), which is held in vesicles, is released into the space
between the two nerves (synapse). It moves across the synapse to the postsynaptic
receptors.
C) If ACh remains at
the receptor, the nerve stays stimulated, causing incontrollable muscle
contractions. This condition is called tetany. An enzyme called
acetylcholinesterase destroys the ACh so tetany does not occur.
Fasciculins:
These toxins attack
cholinergic neurons (those that use ACh as a transmitter) by destroying
acetylcholinesterase (AChE). ACh therefore cannot be broken down and stays in
the receptor. This causes tetany, which can lead to death. The toxins have been
called fasciculins since after injection into mice, they cause severe,
generalized and long-lasting (5-7 h) fasciculations.
Snake example: found
mostly in venom of Mambas and some rattlesnakes
Dendrotoxins:
Dendrotoxins inhibit
neurotransmissions by blocking the exchange of positive and negative ions
across the neuronal membrane lead to no nerve impulse, thereby paralysing the
nerves.
Snake example: Mambas
α-neurotoxins:
This is a large group
of toxins, with over 100 postsynaptic neurotoxins having been identified and
sequenced.[8] α-neurotoxins also attack cholinergic neurons. They mimic the
shape of the acetylcholine molecule and therefore fit into the receptors → they
block the ACh flow → feeling of numbness and paralysis.
Snake examples:
- King Cobra (known as
hannahtoxin containing α-neurotoxins)[9]
- Sea snake (known as
erabutoxin)
- Many-banded krait
(known as α-Bungarotoxin)
- Cobras (known as
cobratoxin),
Phospholipases:
Phospholipase is an
enzyme that transforms the phospholipid molecule into a lysophospholipid (soap)
==> the new molecule attracts and binds fat and ruptures cell membranes.
Snake example: Japanese
Habu
Cardiotoxins:
Cardiotoxins are
components that are specifically toxic to the heart. They bind to particular
sites on the surface of muscle cells and cause depolarisation ==> the toxin
prevents muscle contraction. These toxins may cause the heart to beat
irregularly or stop beating, causing death.
Snake example: King
Cobra, Mambas, and some members of Naja genus
Hemotoxins:
The toxin causes hemolysis,
or destruction of red blood cells (erythrocytes).
Snake example: most
Vipers and the many members of Naja genus.
EVOLUTION
Snake venom consists of many different
toxin proteins: these can either have enzymatic activity, which typically
assists in digestion, or can be shorter peptides that are used to immobilize
prey. [10] Toxin proteins make up many multigene families, and arose from gene
recruitment of proteins that do not code for toxins, followed by extensive
evolutionary modification. [11][12][13] Toxin evolution follows the
birth-and-death model of gene families, where duplication followed by
functional diversification results in the creation of structurally related
proteins that have slightly different functions. It is thought that venom as a
way to immobilize prey was beneficial in allowing the uncoupling of feeding
system and locomotion, which are coupled in the Haenophidians, which then
enabled snakes with venom systems to colonize open areas.[14] Venom continue to
evolve as specific toxins are modified to target a specific prey, and it is
found that toxins vary according to diet in some species.[15][16]
The presence of enzymes
in snake venom was once believed to be an adaptation to assist digestion.
However, studies of the western diamondback rattlesnake, a snake with highly
proteolytic venom, show that venom has no impact on the time required for food
to pass through the gut.[17]
IMMUNITY
Among snakes
The question whether
individual snakes are immune to their own venom is not yet definitely settled,
though there is a known example of a cobra which self-envenomated, resulting in
a large abscess requiring surgical intervention but showing none of the other
effects that would have proven rapidly lethal in prey species or humans.[19]
Furthermore, certain harmless species, such as the North American Lampropeltis
getula and the Brazilian Rhacidelus brazili, are proof against the venom of the
crotalines which frequent the same districts, and which they are able to
overpower and feed upon. The Tropical Rat Snake, Spilotes variabilis, is the
enemy of the Fer-de-lance in St. Lucia, and it is said[by whom?] that in their
encounters the Tropical Rat Snake is invariably the victor. Repeated
experiments have shown the European Common Snake, Tropidonotus natrix, not to
be affected by the bite of Vipera berus and Vipera aspis, this being due to the
presence, in the blood of the harmless snake, of toxic principles secreted by
the parotid and labial glands, and analogous to those of the venom of these
vipers. Several North American species of Rat snakes as well as King snakes
have proven to be immune or highly resistant to the venom of rattlesnake
species.
Among other animals
The Hedgehog, the
Mongoose, the Honey Badger, the Secretary Bird and a few other birds that feed
on snakes are known to be immune to a dose of snake venom. Whether the pig may
be considered so is still uncertain, although it is well known that, owing to
its subcutaneous layer of fat, it is often bitten without ill effect. The
garden dormouse (Eliomys quercinus) has recently been added to the list of
animals refractory to viper venom. Some populations of California Ground
Squirrel are at least partially immune to Rattlesnake venom as adults.
Among humans
The acquisition of
human immunity against snake venom is one of the oldest forms of vaccinology
known to date (about AD 60, Psylli Tribe). Research into development of
vaccines that will lead to immunity is ongoing. Bill Haast, owner and director
of the Miami Serpentarium injected himself with snake venom during most of his
adult life, in an effort to build up an immunity to a broad array of venomous
snakes. It is a practice known as mithridatism. Haast lived to age 100, and
survived a reported 172 snake bites. He donated his blood to be used in
treating snake-bite victims when a suitable anti-venom was not available. More
than twenty of those individuals recovered.[20][21][22]
MEDICINAL PROPERTY
1) CANCER
THERAPY
Snake venoms are supposed to be the
most complex of animal secretions containing a vast number of compounds with
different pharmacological and biochemical activities. Literature shows that
cobra venom components especially DNAase and RNAase and other enzymes inhibit
cancer growth. A PROTEIN found in copperhead snake venom dramatically retards
the growth of breast tumours. In studies with mice implanted with human breast
cancer cells, a 60 to 70 per cent reduction in the growth rate of the breast
tumours and a 90 per cent reduction of tumours that spread to the lungs was
found in rodents treated with the protein. However, it will take at least 18
months before the venom protein will be ready to test on patients. The
copperhead protein acts by inhibiting the development of new blood vessels to
nourish the tumours and by putting tumour cells into a "suspended state of
animation". Prof Markland said the dual action helped prevent the spread
of cancer, a process called metastasis.
When first diagnosed
with breast cancer, many women already have metastatic disease, which means
that the cancer has spread to another site such as the lymph nodes, brain or
bone.
Called contortrostatin,
CN, the protein is purified from the venom of the southern copperhead and is
one of a cocktail used by the snake to immobilise prey, keeping blood fluid so
that other damaging proteins can spread through the body. Snake venoms in general are loaded with
proteins, many of which lead to tissue destruction at the site of the bite. The
mice trials had not revealed any side-effects other than local bleeding. CN belongs
to a class of proteins known as disintegrins, so named because they disrupt the
function of certain other proteins, called integrins, on the surface of cells
that enable them to stick together.
CN should be
administered periodically over time in the hope of shrinking the tumour to a
size is effective in retarding the spread of tumour cells because it inhibits
their adhesion to and invasion of normal cells. CN would need to be
administered per where treatment could be scaled back or stopped.
2) IN
STROKE
A stroke happens when blood flow to the
brain is interrupted. Lack of oxygen and food to the brain can lead to serious
central nervous system impairments and even death. Snake venom has been found
to have properties that can be useful in the treatment of strokes. A substance
called ANCROD, derived from snake venom, allows stroke victims to recover their
mental and physical abilities. Researchers found that more than 40% of patients
who received ANCROD recovered all of their mental faculties versus more than
30% for placebo patients. The researchers hope that snake venom may provide an
alternative to Tissue Plasminogen Activator (TPA) which currently is the only
FDA-approved treatment for acute stokes.
ANCROD is a substance formulated
from the venom of the Malayan pit viper. In previous observations, scientists
had noted that the blood of people bitten by the snake failed to clot. Since
stokes are caused by blood clots, researchers were hopeful that this
anticoagulant might have applications in stoke victims.
The most striking difference
between ANCROD and TPA is the method of administration. TPA is normally
injected in a single dose, preferably in the first three hours after the onset
of a stroke. ANCROD, on the other hand, is administered by IV over a 3 to 5 day
period.
While TPA dissolves clots that
cause strokes, ANCROD works by reducing the level of fibrinogen in the blood.
Since fibrinogen is the clotting factor in the body, lower levels allow the
blood to flow more freely through the blood vessels, thereby reducing the
chances for clotting.
Scientists found that those
patients whose fibrinogen was reduced and maintained at a target level had the
most successful treatment after a stroke. The amount necessary to produce this
result was determined by both the body weight of the patient and the relative
amount of fibrinogen in the patient's blood. During the treatment period, the
additional amount of ANCROD needed was based on the relative level of
fibrinogen present in the blood at that time.
The target level was 40-70
milligrams of fibrinogen per deciliter of blood. Doctors found that if this
level was maintained in the body, the patients regained their mental faculties
after the stroke, had less chance of bleeding, and had less chance of another
stroke during the therapy period.
Researchers hope to provide an
alternative to the use of TPA. They speculate that having a wider range of
treatments will benefit patients. Depending on the kind of stoke and the
particular patient, one of the two could be more effective than the other.
Patients participated in a
follow-up three months after the stroke. Various mental and physical tests were
performed to gauge whether these patients had returned to normal and regained
their mental faculties. Researchers noted that patients who received ANCROD
were more likely to have a higher risk of bleeding in the brain compared to TPA
patients.
3) BRAIN
DISORDERS
The paralyzing effects of the venom of African mamba snakes can be so
powerful that bites from these snakes have been known to topple giraffes and
lions, and can kill a person within 20 minutes. But that hasn’t stopped
biochemist Dr. Krishna Baksi of the Universidad Central Del Caribe in Puerto
Rico from working with the venom of these snakes. With funding from the NIH
National Institute of General Medical Sciences, Dr. Baksi is trying to figure
out what enables proteins in the mamba venom from latching on so tightly and
specifically to certain structures called receptors, which jut out of the
surface of brain and nerve cells. The brain uses certain kinds of these
receptors to receive the chemical signals that let it learn, form memories,
perceive pain, and do many other functions. Nerve cells use the same receptor
type to pass on signals to neighboring muscles that trigger them to contract or
stay at rest, and affect breathing and heart beat rates. There are five known
subtypes of these receptors, each of which are thought to play a role in
various diseases, including asthma, Parkinson’s disease, Alzheimer’s disease
and certain pain disorders. So researchers are eager to find drugs that can
alter the actions of these receptors.
But their efforts have been
hampered by an inability to find compounds that act specifically on only one
type of receptor--you don’t want a drug that acts on the receptor involved with
Alzheimer’s disease if you have Parkinson’s disease, for example. And that’s
where the mamba snake comes in. Its venom has proteins that are highly specific
for which receptors they will latch on to. By studying the structure of these
proteins, Dr. Baksi hopes to have results that drug makers can use to design
new and more selective drugs for a wide range of neurological disorders.
4) AIDS
Snake venom contains Phospholipase
A2 (PLA2)[11,16], which protect human primary blood leukocytes from the
replication of various macrophage and T cell-tropic human immunodeficiency
virus 1 (HIV-1) strains. PLA2 which is found in the venom of many snakes has
been shown to block viral entry into cells before virion uncoating through
prevention of intracellular release of viral capsid protein [16]. This is
mainly due to the specific interaction of PLA2 to host cells and not due to
catalytic activity.
Immunokine - an oxidized derivative of
alpha - cobra toxin (Naja naja siamensis), has been shown to inhibit the
infection of lymphocytes by HIV and Feline immunodeficiency virus (FIV) through
chemokine receptors (CCR 5 and CXCR 4).
L- amino acid oxidase (LAO), present in the
venom of Trimeresurus stejnegeri[18], C. Atrox, P. australis[19]; inhibits
infection and replication of HIV virus through P24 antigen in a dose dependant
manner[18]. P24 antigen is a core protein of HIV and its level associates with
viral load[20]. Besides the binding of protein to cell membrane, hydrogen
peroxide (H2O2) produced as a free radical could inhibit the
infection/replication of HIV, thereby further enhancing the anti viral
activity. In contrast, catalase - a scavenger of H2O2, reduces the anti- viral
activity [18].
Protein fragment isolated from Oxyuranus
scutellatus snake venom is a potent inhibitor of p24 antigen and blocks viral
replication of resistant strains [21].
Snake venom contains metalloprotease
inhibitors[16,22] which could prevent the production of new viruses through
inhibition of protease enzymes. HIV infects a CD4 cell of a person's body and
then it copies its own genetic code into the cell's DNA. Then, CD4 cell is
"programmed" to make new HIV genetic material and proteins. These
proteins are degraded by HIV protease enzyme and again these proteins are used
to make functional new HIV particles. Protease inhibitors are used to block the
protease enzyme and prevent the cell from producing new viruses.
P-glycoprotein (P-gp),
a membrane protein, is an energy-dependent efflux transporter driven by ATP
hydrolysis[23]. P-gp transports a wide range of substances with diverse
chemical structures. In general, P-gp substrates appear to be lipophilic and
amphiphatic, and are recognized to play an important role in processes of absorption,
distribution, metabolism, and excretion of many clinically important drugs in
humans [23]. Because of its importance in pharmacokinetics, inhibition or
induction of P-gp by various components of snake venom can lead to significant
drug-drug interactions, thereby changing the systemic or target tissue exposure
of the protease inhibitors. At the same time one has to remember genetic
polymorphism of P-gp,[23] which has also been recorded recently, because it may
affect drug disposition and produce variable drug effects.
5)
Analgesic effect
Scientists have used the venom of Africa's
lethal black mamba to produce an effective pain relief without toxic side
effects. peptides isolated from black mamba venom may be a safer pain killer
than morphine.
In
mice at least, the peptides bypass the receptors in the brain that are targeted
by morphine and other opioid compounds which sometimes cause side-effects like
breathing difficulties or nausea.
Nor
do the peptides pose the same risk of addiction or drug abuse. natural
peptides, mambalgins, from the venom of the snake Black Mamba that are able to
significantly reduce pain in mice without toxic effect, It is remarkable that
this was made possible from the deadly venom of one of the most venomous
snakes," she says.
"(It)
is surprising that mambalgins, which represent less than 0.5 per cent of the
total venom protein content, has analgesic (pain-relief) properties without
neurotoxicity in mice, whereas the total venom of black mamba is lethal and
among the most neurotoxic ones."
Morphine
is often regarded as the best drug to relieve severe pain and suffering, but it
has several side effects and can be habit-forming.
The
black mamba's venom is among the fastest acting of any snake species, and a
bite will be fatal if not treated with antivenom - the poison attacking the
central nervous system and causing respiratory paralysis.
Mice
are among the agile adder's favourite prey in the wild in eastern and southern
Africa.
6)
ANTI AGING
A topical treatment incorporating imitation
snake venom is being marketed as an alternative to Botox. The results of this
product, called Wrinkle Defence, are typical of topical treatments in their
cumulative effect. While Botox injections are immediately active on the facial muscles,
the “freezing” results of this topical begin to appear after about two weeks.
It is claimed that Wrinkle Defence visibly reduces wrinkles by 52%.